Clinical Trial

MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study was designed to compare the efficacy and safety of Becotatug Vedotin (MRG003) combined with Pucotenlimab as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-24.
Trial Details
NCT Number NCT07381699
Lead Sponsor West China Hospital
Conditions Nasopharyngeal Cancinoma (NPC)
Enrollment 30 participants
Start Date 2026-02-01
Primary Completion 2028-02-01 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-13